Arovella Therapeutics Ltd (ASX: ALA) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Arovella Therapeutics Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $115.52 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 1.05 billion
Earnings per share -0.013
Dividend per share N/A
Year To Date Return -8.70%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Arovella Therapeutics Ltd (ASX: ALA)
    Latest News

    Share Market News

    Suda Pharmaceuticals share price soars 200% on TGA approval

    The Suda Pharmaceuticals share price is soaring over 200% following TGA approval for its insomnia treatment product, ZolpiMist.

    Read more »

    ALA ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Arovella Therapeutics Ltd

    Arovella Therapeutics Ltd is a biotechnology company focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumours.

    ALA Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    23 May 2024 $0.11 $0.01 9.52% 2,549,608 $0.11 $0.12 $0.11
    22 May 2024 $0.11 $-0.01 -8.70% 1,705,782 $0.12 $0.12 $0.11
    21 May 2024 $0.12 $0.00 0.00% 678,525 $0.12 $0.12 $0.11
    20 May 2024 $0.12 $0.00 0.00% 672,835 $0.12 $0.12 $0.11
    17 May 2024 $0.12 $0.00 0.00% 1,488,407 $0.12 $0.13 $0.12
    16 May 2024 $0.12 $0.01 9.09% 1,017,054 $0.11 $0.12 $0.11
    15 May 2024 $0.11 $-0.01 -8.33% 1,308,852 $0.12 $0.12 $0.11
    14 May 2024 $0.12 $-0.01 -8.00% 487,521 $0.12 $0.13 $0.12
    13 May 2024 $0.13 $0.01 8.33% 1,130,488 $0.13 $0.13 $0.12
    10 May 2024 $0.12 $-0.01 -8.00% 749,230 $0.13 $0.13 $0.12
    09 May 2024 $0.13 $0.00 0.00% 1,049,740 $0.13 $0.13 $0.12
    08 May 2024 $0.13 $0.00 0.00% 519,709 $0.13 $0.13 $0.12
    07 May 2024 $0.13 $0.00 0.00% 652,270 $0.13 $0.13 $0.12
    06 May 2024 $0.13 $-0.01 -7.69% 2,163,206 $0.13 $0.14 $0.13
    03 May 2024 $0.13 $0.01 8.33% 1,063,102 $0.13 $0.13 $0.12
    02 May 2024 $0.12 $0.00 0.00% 664,667 $0.12 $0.13 $0.12
    01 May 2024 $0.12 $-0.01 -8.00% 569,944 $0.12 $0.13 $0.12
    30 Apr 2024 $0.13 $0.01 8.33% 941,962 $0.13 $0.13 $0.12
    29 Apr 2024 $0.12 $0.00 0.00% 396,116 $0.13 $0.13 $0.12
    26 Apr 2024 $0.12 $0.00 0.00% 3,063,356 $0.12 $0.13 $0.12
    24 Apr 2024 $0.12 $0.00 0.00% 1,618,958 $0.12 $0.12 $0.11
    23 Apr 2024 $0.12 $0.00 0.00% 797,989 $0.12 $0.12 $0.11

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    28 Mar 2024 Gary Phillips Buy 66,666 $10,000
    On-market trade.
    28 Mar 2024 Thomas (Tom) Duthy Buy 103,000 $14,935
    On-market trade.
    27 Mar 2024 Michael Baker Buy 220,000 $31,289
    On-market trade.
    29 Dec 2023 Michael Baker Buy 587,824 $67,599
    Exercise of options.
    29 Dec 2023 Michael Baker Exercise 2,800,000 $322,000
    Exercise of options.
    04 Dec 2023 Thomas (Tom) Duthy Issued 319,000 $28,072
    Director remuneration.
    04 Dec 2023 Michael Baker Issued 2,178,531 $191,710
    Issue of options.
    04 Dec 2023 Debora Barton Issued 618,000 $54,384
    Director remuneration. As per announcement on 08-12-2023
    04 Dec 2023 Elizabeth Stoner Issued 618,000 $54,384
    Director remuneration.
    04 Dec 2023 Gary Phillips Issued 618,000 $54,384
    Director remuneration. AS per announcement on 08-12-2023
    24 Aug 2023 Thomas (Tom) Duthy Issued 2,250,000 $103,500
    Issue of securities.
    24 Aug 2023 Thomas (Tom) Duthy Issued 6,521,739 $299,999
    Issue of options.
    12 Jul 2023 Michael Baker Issued 666,666 $29,999
    Participation in share purchase plan.
    12 Jul 2023 Gary Phillips Issued 222,222 $9,999
    Participation in share purchase plan.
    12 Jul 2023 Thomas (Tom) Duthy Issued 444,444 $19,999
    Participation in share purchase plan.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Gary Phillips Non-Executive Director Jul 2022
    Mr Phillips has more than 40 years of operational management experience in the pharmaceutical and healthcare industry in Europe, Asia and Australia. After managing country operations for Novartis in Eastern Europe and Asia, Gary came to Australia as CEO of Novartis in 2001, successfully launching leading oncology and ophthalmology products. He joined Pharmaxis in December 2003 when the company listed on the Australian Securities Exchange. Following his appointment as Pharmaxis CEO in 2013, Gary has overseen a company restructure focused on building value, forging commercial partnerships and fostering the development of the Pharmaxis product pipeline. Pharmaxis has commercial partnerships in place with Pharma companies for drugs in asthma and cystic fibrosis and a pipeline with clinical stage assets in oncology, fibrosis and inflammation.
    Dr Thomas (Tom) Duthy Non-Executive ChairmanNon-Executive Director Mar 2023
    Dr Duthy has over 18 years of direct financial markets experience and is the Founder
    and CEO of Nemean Group Pty Ltd, a boutique corporate advisory and investor relations firm specialising in the life sciences and technology sectors. Tom spent ten years as a leading sell-side Healthcare & Biotechnology analyst at Taylor Collison Limited, focused mainly on small cap companies.
    Mr David Simmonds Non-Executive Director Mar 2019
    Mr Simmonds was a senior audit partner with Ernst & Young. David led the Capital Markets desk in Australia with responsibility for overseeing or reviewing all Australian cross border fundraisings. As an audit partner, David was involved in several high-profile businesses including Ramsay Health Care Ltd, John Fairfax Holdings and Commonwealth Bank of Australia and also was audit partner for the Australian operations of the leading US technology companies Hewlett Packard, Sun Microsystems and Oracle. David was a member of the Board and chaired the Audit, Risk and Finance Committee of MS Research Australia, the largest national not-for-profit body dedicated to funding and coordinating multiple sclerosis research in Australia.
    Dr Michael Baker Chief Executive OfficerManaging Director Jan 2020
    Dr Baker has over 15 years of experience in scientific research, drug developmentand venture investing. He was an Investment Manager with leading Australian life science fund, BioScience Managers, responsible for deal sourcing form networks, conferences, universities, and research institutes. He also conducted due diligence to shortlist investment opportunities and played an active role in managing portfolio companies.
    Dr Debora Barton Non-Executive Director Aug 2021
    Dr Barton has over 20 years of oncology experience, which includes 9 years of clinical
    management of oncology patients and enrolling patients in clinical trials in academia. In the pharmaceutical industry, she has experience in medical affairs and clinical development in both large pharmaceutical and small biotech companies, including regulatory interactions in the USA, Europe, Australia, and several countries around the world. She has accomplished an innovative oncology product submission and subsequent marketing authorisation in the US and Europe and has built innovative clinical development plans coupled with clinical/safety teams' infrastructure in small biotech.
    Dr Elizabeth Stoner Non-Executive Director Nov 2021
    Dr Stoner has over 30 years' experience in the life-science sector. She is currently an
    executive partner at MPM Capital, a leading US healthcare investment firm. In her role, Dr Stoner serves as a clinical advisor to several of MPM Capital's portfolio companies, including AlloVir, and Rhythm Pharmaceuticals. Additionally, Dr Stoner served as the interim CEO of Semma Therapeutics. Prior to joining MPM Capital, Dr Stoner was a Senior Vice President of Global Clinical Development Operations at Merck Research Laboratories where she was responsible for its clinical development activities in more than 40 countries. Dr Stoner currently serves on the board of Triplett Therapeutics. She is also a member of the Albert Einstein College of Medicine Board of Governors, and the Weill Cornell Medical College Clinical and Translational Science Centre External Advisory Board.
    Mr Tim Luscombe Chief Financial OfficerCompany Secretary Dec 2023
    -
    Tim Luscombe Chief Financial OfficerCompany Secretary
    -
    Dr Nicole van der Weerden Chief Operating Officer
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    The Trust Company (Australia) Limited <Mbf A/C> 55,135,161 6.13%
    Mann Beef Pty Ltd 39,555,555 4.40%
    UBS Nominees Pty Ltd 20,620,196 2.29%
    Blackburne Capital Pty Ltd <Blackburne Capital A/C> 19,175,000 2.13%
    Dylide Pty Ltd 15,666,666 1.74%
    Mann Beef Pty Ltd <Lochwall Super Fund A/C> 11,350,102 1.26%
    M & M Stock One Pty Ltd <The M & M Stock One A/C> 11,201,081 1.25%
    Kamala Holdings Pty Ltd <The Kamala 1994 S/F A/C> 10,394,286 1.16%
    Mr Neil Donald Delroy <The Ndd Investment A/C> 10,322,222 1.15%
    Moovnup Pty Ltd <Moovnup A/C> 10,145,462 1.13%
    Widerange Corporation Pty Ltd 10,140,789 1.13%
    Mr Brendan John Martin & Mrs Sharon Ann Martin <Jaknic Super A/C> 9,564,970 1.06%
    S3 Consortium Pty Ltd 8,800,000 0.98%
    The Trust Company (Australia) Limited <Mof A/C> 8,600,444 0.96%
    Mr Marvin Weng Chung Leong & Mrs Tien Ju Yeap <Marju Super A/C> 7,503,078 0.83%
    Murray James Way Pty Ltd 7,320,472 0.81%
    Mr Timothy William Cooper & Mrs Kellie Maree Cooper 7,255,000 0.81%
    Transmin Pty Ltd 6,948,805 0.77%
    Citicorp Nominees Pty Limited 6,542,314 0.73%
    Shared Office Services Pty Ltd <Philanne Super A/C> 6,298,245 0.70%

    Profile

    since

    Note